NVAX vs. IOVA, DNLI, TWST, RLAY, ADPT, RGEN, EXAS, EXEL, HALO, and IONS
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Iovance Biotherapeutics (NASDAQ:IOVA) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
Novavax has a net margin of -40.01% compared to Novavax's net margin of -23,615.70%. Iovance Biotherapeutics' return on equity of 0.00% beat Novavax's return on equity.
Iovance Biotherapeutics has higher earnings, but lower revenue than Novavax. Novavax is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Novavax has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
Novavax received 283 more outperform votes than Iovance Biotherapeutics when rated by MarketBeat users. However, 74.57% of users gave Iovance Biotherapeutics an outperform vote while only 74.14% of users gave Novavax an outperform vote.
Iovance Biotherapeutics presently has a consensus target price of $24.64, suggesting a potential upside of 216.66%. Novavax has a consensus target price of $17.50, suggesting a potential downside of 3.69%. Given Novavax's stronger consensus rating and higher possible upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Novavax.
In the previous week, Novavax had 10 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 20 mentions for Novavax and 10 mentions for Iovance Biotherapeutics. Novavax's average media sentiment score of 1.00 beat Iovance Biotherapeutics' score of 0.64 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 10.4% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 0.9% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Iovance Biotherapeutics beats Novavax on 11 of the 18 factors compared between the two stocks.
Get Novavax News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
